The Effect of Amiloride and Spironolactone in Patients With Hypertension
NCT ID: NCT01388088
Last Updated: 2012-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
23 participants
INTERVENTIONAL
2010-09-30
2012-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators will examine the changes in the cardiovascular system using a Sphygmocor-scanner.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables
NCT01195805
The Effect of Amiloride and Spironolactone in Healthy Persons
NCT00857909
Double Blind Crossover Comparison of Diuretics in the Young
NCT00429897
A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure
NCT03984591
The Comparison Between Spironolactone and Indapamide Monotherapy or in Combination With Amlodipine to Reduce the Risk of Heart Failure
NCT04455178
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Renal function (GFR, u-AQP2, u-ENaCĪ², u-cAMP, u-PGE2, CH20, FENa, FEK),
2. Pulsewavevelocity, augmentation index and centralt bloodpressure,
3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and
4. Ambulatory blood pressure
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Spironolactone
Increases the level of potassium
Spironolactone
25 mg twice a day
Amiloride
Increases the level of potassium
Amiloride
5 mg twice a day
Placebo
Placebo
twice a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Spironolactone
25 mg twice a day
Amiloride
5 mg twice a day
Placebo
twice a day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 45-70
* BMI: 18,5-30
Exclusion Criteria
* Drug or alcohol abuse
* Abnormal findings in the screening procedure
45 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Erling Bjerregaard Pedersen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Erling Bjerregaard Pedersen
Proffesor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Solveig K Matthesen, Cand.Med
Role: PRINCIPAL_INVESTIGATOR
Medical Research Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Medical Research
Holstebro, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MED.RES.HOS.2010.02.SKM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.